Apart from their hypoglycemic action, dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide receptor (GLP-1R) agonists have been demonstrated to improve inflammatory markers, oxidative stress, endothelial function and, to some extent, the atheroprotective features in patients with T2DM [123]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.